Fwd: OncoKB New Data Release - December 19, 2024
Contact OncoKB
Data Release v4.24
December 19, 2024
What's New
Update to our FDA-Approved Oncology Therapies page
Updated Therapeutic Implications:
Promotion of tumor type-specific level of evidence for an alteration
Level 1: NRG1 Fusions in non-small cell lung cancer and pancreatic adenocarcinoma promoted from Level 3A to Level 1 based on FDA approval of Zenocutuzumab in patients with advanced, unresectable or metastatic non-small cell lung cancer or pancreatic adenocarcinoma harboring an NRG1 gene fusion (Abstract: Schram, A. et al. Abstract# 1618P, Annals of Oncol. 2023)
Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)
Level 3A: Addition of Zanidatamab to ERBB2 Amplification in biliary tract cancer based on FDA approval of Zanidatamab in HER2-positive (IHC 3+) biliary tract cancer (PMID: 37276871)
Sensitivity-associated evidence currently in OncoKB™ for ERBB2 Amplification (Level 2 in biliary tract cancer - Trastuzumab + Pertuzumab, Tucatinib + Trastuzumab)
Gene Curation:
Addition of 3 new genes:
AIPCASRGEN1
We're Here to Help
As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you. You can reach us at con...@oncokb.org
